Us Bancorp \De\ Seagen Inc. Transaction History

Us Bancorp \De\

  • $71.8 Billion
  • Q1 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 03, 2023
SELL
$191.51 - $216.16 $98,244 - $110,890
-513 Reduced 6.9%
6,920 $1.47 Million
Q2 2023

Aug 09, 2023
SELL
$187.64 - $206.25 $73,179 - $80,437
-390 Reduced 4.99%
7,433 $1.43 Million
Q1 2023

May 09, 2023
SELL
$127.59 - $203.08 $435,209 - $692,705
-3,411 Reduced 30.36%
7,823 $1.58 Million
Q4 2022

Feb 13, 2023
SELL
$117.37 - $139.17 $94,600 - $112,171
-806 Reduced 6.69%
11,234 $1.44 Million
Q3 2022

Oct 27, 2022
SELL
$135.27 - $180.11 $1.14 Million - $1.52 Million
-8,449 Reduced 41.24%
12,040 $1.65 Million
Q2 2022

Aug 01, 2022
SELL
$108.81 - $179.33 $177,033 - $291,769
-1,627 Reduced 7.36%
20,489 $3.62 Million
Q1 2022

May 11, 2022
BUY
$119.61 - $157.85 $145,684 - $192,261
1,218 Added 5.83%
22,116 $3.19 Million
Q4 2021

Feb 11, 2022
BUY
$142.57 - $190.86 $14,114 - $18,895
99 Added 0.48%
20,898 $3.23 Million
Q3 2021

Nov 10, 2021
BUY
$142.45 - $169.82 $194,444 - $231,804
1,365 Added 7.02%
20,799 $3.53 Million
Q2 2021

Aug 05, 2021
BUY
$135.08 - $161.1 $414,965 - $494,899
3,072 Added 18.78%
19,434 $3.07 Million
Q1 2021

Apr 28, 2021
BUY
$137.51 - $190.8 $362,751 - $503,330
2,638 Added 19.22%
16,362 $2.27 Million
Q4 2020

Feb 04, 2021
BUY
$164.63 - $211.93 $2.26 Million - $2.91 Million
13,724 New
13,724 $2.4 Million

Others Institutions Holding SGEN

# of Institutions
40
Shares Held
1.26M
Call Options Held
23K
Put Options Held
55.2K
View Full List

About Seagen Inc.

SGEN Quotes by TradingView
  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email